Ion channels, transporters, and pumps as targets for heart failure therapy

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 4, 2009, Pages 273-278

  Doshi, Darshan ^a   Marx, Steven O ^a,b  

^a Division of Cardiology   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Arrhythmias; Heart failure; Ion channels; Pumps; Transporters; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; ENALAPRIL; ION CHANNEL; METOPROLOL; POTASSIUM CHANNEL; RANOLAZINE; SODIUM ION; SODIUM PROTON EXCHANGE PROTEIN;

CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HUMAN; MEMBRANE POLARIZATION AND DEPOLARIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; ARRHYTHMIAS, CARDIAC; HEART FAILURE; HUMANS; ION CHANNEL GATING; ION CHANNELS; MYOCARDIAL CONTRACTION;

EID: 74949129535     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181a1b9c7     Document Type: Review

References (79)

1. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
2. Kass DA. Rescuing a failing heart: putting on the squeeze. Nat Med. 2009; 15:24-25.
3. Nattel S, Maguy A, Le Bouter S, et al. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 2007;87:425-456. (Pubitemid 47084677)
4. Baartscheer A, Schumacher CA, van Borren MM, et al. Increased Na+/ H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res. 2003;57:1015-1024.
5. Baartscheer A, Hardziyenka M, Schumacher CA, et al. Chronic inhibition of the Na+/H+-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Br J Pharmacol. 2008; 154:1266-1275.
6. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res. 2004;61:208-217.
7. Nabauer M, Kaab S. Potassium channel down-regulation in heart failure. Cardiovasc Res. 1998;37:324-334.
8. Fabiato A, Fabiato F. Calcium and cardiac excitation-contraction coupling. Annu Rev Physiol. 1979;41:473-484.
9. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991;251:283-287.
10. Jayaraman T, Brillantes AM, Timerman AP, et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem. 1992;267:9474-9477.
11. Kaftan E, Marks AR, Ehrlich BE. Effects of rapamycin on ryanodine receptor/Ca(2+)-release channels from cardiac muscle. Circ Res. 1996;78: 990-997.
12. Timerman AP, Jayaraman T, Wiederrecht G, et al. The ryanodine receptor from canine heart sarcoplasmic reticulum is associated with a novel FK- 506 binding protein. Biochem Biophys Res Commun. 1994;198:701-706.
13. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
14. Marx SO, Gaburjakova J, Gaburjakova M, et al. Coupled gating between cardiac calcium release channels (ryanodine receptors). Circ Res. 2001; 88:1151-1158.
15. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415: 198-205.
16. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521-555.
17. Anderson ME. Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther. 2005;106:39-55.
18. Pitt GS. Calmodulin and CaMKII as molecular switches for cardiac ion channels. Cardiovasc Res. 2007;73:641-647.
19. Hudmon A, Schulman H, Kim J, et al. CaMKII tethers to L-type Ca2+ channels, establishing a local and dedicated integrator of Ca2+ signals for facilitation. J Cell Biol. 2005;171:537-547. Res. 2004;94:e61-e70.
20. James P, Inui M, Tada M, et al. Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum. Nature. 1989;342:90-92.
21. Sasaki T, Inui M, Kimura Y, et al. Molecular mechanism of regulation of Ca2+ pump ATPase by phospholamban in cardiac sarcoplasmic reticulum. Effects of synthetic phospholamban peptides on Ca2+ pump ATPase. J Biol Chem. 1992;267:1674-1679.
22. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992;85:1046-1055.
23. Beuckelmann DJ, Nabauer M, Kruger C, et al. Altered diastolic [Ca2+]i handling in human ventricular myocytes from patients with terminal heart failure. Am Heart J. 1995;129:684-689.
24. Gomez AM, Valdivia HH, Cheng H, et al. Defective excitationcontraction coupling in experimental cardiac hypertrophy and heart failure. Science. 1997;276:800-806.
25. Pieske B, Maier LS, Bers DM, et al. Ca2+ handling and sarcoplasmic reticulum Ca2+ content in isolated failing and nonfailing human myocardium. Circ Res. 1999;85:38-46.
26. Lehnart SE, Wehrens XH, Reiken S, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005;123:25-35.
27. Wehrens XH, Lehnart SE, Reiken S, et al. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci U S A. 2006;103:511-518.
28. Benkusky NA, Weber CS, Scherman JA, et al. Intact beta-adrenergic response and unmodified progression toward heart failure in mice with genetic ablation of a major protein kinase A phosphorylation site in the cardiac ryanodine receptor. Circ Res. 2007;101:819-829.
29. Lehnart S, Marks AR. Regulation of ryanodine receptors in the heart. Circ Res. 2007;101:746-749.
30. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566-577.
31. Waggoner JR, Kranias EG. Role of phospholamban in the pathogenesis of heart failure. Heart Fail Clin. 2005;1:207-218.
32. Koss KL, Grupp IL, Kranias EG. The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility. Basic Res Cardiol. 1997;92(Suppl 1):17-24.
33. Zarain-Herzberg A, Afzal N, Elimban V, et al. Decreased expression of cardiac sarcoplasmic reticulum Ca(2+)-pump ATPase in congestive heart failure due to myocardial infarction. Mol Cell Biochem. 1996;163-164: 285-290.
34. Cory CR, Grange RW, Houston ME. Role of sarcoplasmic reticulum in loss of load-sensitive relaxation in pressure overload cardiac hypertrophy. Am J Physiol. 1994;266:H68-H78.
35. Kiss E, Ball NA, Kranias EG, et al. Differential changes in cardiac phospholamban and sarcoplasmic reticular Ca(2+)-ATPase protein levels. Effects on Ca2+ transport and mechanics in compensated pressureoverload hypertrophy and congestive heart failure. Circ Res. 1995;77: 759-764.
36. Chu G, Kranias EG. Phospholamban as a therapeutic modality in heart failure. Novartis Found Symp. 2006;274:156-171; Discussion 72-75, 272-276.
37. Pattison JS, Waggoner JR, James J, et al. Phospholamban overexpression in transgenic rabbits. Transgenic Res. 2008;17:157-170.
38. Luo W, Chu G, Sato Y, et al. Transgenic approaches to define the functional role of dual site phospholamban phosphorylation. J Biol Chem. 1998;273:4734-4739.
39. Baker DL, Hashimoto K, Grupp IL, et al. Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res. 1998;83:1205-1214.
40. Schultz Jel J, Glascock BJ, Witt SA, et al. Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am J Physiol Heart Circ Physiol. 2004; 286:H1146-H1153.
41. Mercadier JJ, Lompre AM, Duc P, et al. Altered sarcoplasmic reticulum Ca2(+)- ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 1990;85:305-309.
42. Linck B, Boknik P, Eschenhagen T, et al. Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts. Cardiovasc Res. 1996;31:625-632.
43. Schwinger RH, Bohm M, Schmidt U, et al. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)- ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 1995;92:3220-3228.
44. Limas CJ, Olivari MT, Goldenberg IF, et al. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res. 1987;21:601-605.
45. Meyer M, Schillinger W, Pieske B, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995;92:778-784.
46. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295-1302.
47. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355. (Pubitemid 26152713)
48. Reiken S, Wehrens XH, Vest JA, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003;107:2459-2466.
49. Kohno M, Yano M, Kobayashi S, et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol. 2003;284:H1035-H1042.
50. Yano M, Kobayashi S, Kohno M, et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation. 2003;107:477-484.
51. Wehrens XH, Lehnart SE, Reiken S, et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci U S A. 2005;102:9607-9612.
52. Wehrens XH, Lehnart SE, Reiken SR, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004;304:292-296.
53. Tsuji T, Del Monte F, Yoshikawa Y, et al. Rescue of Ca2+ overloadinduced left ventriclur dysfunction by targeted ablation of phospholamban. Am J Physiol Heart Circ Physiol. 2009;296:H310-H317.
54. Prunier F, Kawase Y, Gianni D, et al. Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation. 2008;118:614-624.
55. Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after longterm expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51:1112-1119.
56. Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14:355-367.
57. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res 2008;102:1458-1470.
58. Maltsev VA, Kyle JW, Mishra S, et al. Molecular identity of the late sodium current in adult dog cardiomyocytes identified by Nav1.5 antisense inhibition. Am J Physiol Heart Circ Physiol. 2008;295:H667-H676.
59. Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res. 2002;91:278-280.
60. Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. 2008;295:H2149-H2155.
61. Baartscheer A, van Borren MM. Sodium ion transporters as new therapeutic targets in heart failure. Cardiovasc Hematol Agents Med Chem. 2008;6:229-236.
62. Karmazyn M, Kilic A, Javadov S. The role of NHE-1 in myocardial hypertrophy and remodelling. J Mol Cell Cardiol. 2008;44:647-653.
63. Aiello EA, Villa-Abrille MC, Dulce RA, et al. Endothelin-1 stimulates the Na+/Ca2+ exchanger reverse mode through intracellular Na+ (Na+i)- dependent and Na+i-independent pathways. Hypertension. 2005;45: 288-293.
64. Chahine M, Bkaily G, Nader M, et al. NHE-1-dependent intracellular sodium overload in hypertrophic hereditary cardiomyopathy: prevention by NHE-1 inhibitor. J Mol Cell Cardiol. 2005;38:571-582.
65. Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodiumhydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation. 2000;102:3032-3038.
66. Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001;38:1644-1650. (Pubitemid 33065449)
67. Mentzer RM, Jr., Bartels C, Bolli R, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg. 2008;85:1261-1270.
68. Dixon JE, Shi W, Wang HS, et al. Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current. Circ Res. 1996;79:659-668.
69. Brahmajothi MV, Campbell DL, Rasmusson RL, et al. Distinct transient outward potassium current (Ito) phenotypes and distribution of fastinactivating potassium channel alpha subunits in ferret left ventricular myocytes. J Gen Physiol. 1999;113:581-600.
70. Zicha S, Xiao L, Stafford S, et al. Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. J Physiol. 2004;561:735-748.
71. Doggrell SA. Tedisamil: master switch of nature? Expert Opin Investig Drugs. 2001;10:129-138.
72. Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc Drugs Ther. 1993;7:233-240.
73. Hermann HP, Ohler A, Just H, et al. Cardiac and hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestive heart failure due to dilated cardiomyopathy. J Cardiovasc Pharmacol. 1998;32:969-974.
74. Akao M, Ohler A, O'Rourke B, et al. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res. 2001;88:1267-1275.
75. Kane GC, Liu XK, Yamada S, et al. Cardiac KATP channels in health and disease. J Mol Cell Cardiol. 2005;38:937-943.
76. Liu XK, Yamada S, Kane GC, et al. Genetic disruption of Kir6.2, the poreforming subunit of ATP-sensitive K+ channel, predisposes to catecholamine-induced ventricular dysrhythmia. Diabetes. 2004;53(Suppl 3): S165-S168.
77. Yamada S, Kane GC, Behfar A, et al. Protection conferred by myocardial ATPsensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol. 2006;577: 1053-1065.
78. Tammaro P, Ashcroft FM. Keeping the heart going: a new role for KATP channels. J Physiol. 2006;577:767.
79. Mannhold R. KATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev. 2004;24:213-266.